MULTIPLE MYELOMA

Clinical trials of selinexor, which is being explored in several tumor types, have been placed on clinical hold by the FDA.

Lenalidomide has been approved by the FDA as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.

Multiple myeloma expert Kenneth C. Anderson, MD, will serve as president of the American Society of Hematology through the end of this year.

Based on data from 2 phase III trials, the EMA’s CHMP has recommended approval of lenalidomide as a maintenance therapy following autologous stem cell transplant for patients with newly diagnosed multiple myeloma.

Saad Z. Usmani, MD, discusses the POLLUX update and PAVO findings presented at ASH, as well as the latest developments with daratumumab.

Monoclonal Antibodies in Relapsed Multiple Myeloma with Ola Landgren, MD, PhD

Monoclonal Antibodies in Relapsed Multiple Myeloma with Ola Landgren, MD, PhD

Monoclonal Antibodies in Relapsed Multiple Myeloma with Cristina Gasparetto, MD

Monoclonal Antibodies in Relapsed Multiple Myeloma with Cristina Gasparetto, MD

Kevin R. Kelly, MD, PhD, discusses the differences seen between ethnic groups in multiple myeloma diagnosis and response to treatment.

Cristina Gasparetto, MD, discuss treatment considerations and options for patients with multiple myeloma based on 2 case scenarios.

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.

Beginning with bortezomib (Velcade) in 2004, there have been 10 agents approved over the last 12 years for the treatment of patients with multiple myeloma.

Pembrolizumab (Keytruda), pomalidomide (Pomalyst), and dexamethasone had an objective response rate of 65% and a very good partial response or better rate of 29% for patients with relapsed/refractory multiple myeloma, according to phase II findings presented at the 2016 ASH Annual Meeting.

Data from a prospective assessment of minimal residual disease from the phase III CASTOR and POLLUX studies demonstrated at least a 3-fold increase in conversion to negative MRD status with the addition of daratumumab (Darzalex) to standard-of-care regimens in the treatment of patients with relapsed/refractory multiple myeloma.

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses the efficacy seen with venetoclax in multiple myeloma during the ASH Annual Meeting 2016.